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Abstract
Mycobacterium tuberculosis is successfully evolving antibiotic resistance, threatening attempts at
tuberculosis epidemic control. Mechanisms of resistance, including the genetic changes favored by
selection in resistant isolates, are incompletely understood. Using 116 newly and 7 previously
sequenced M. tuberculosis genomes, we identified genomewide signatures of positive selection
specific to the 47 resistant genomes. By searching for convergent evolution, the independent
fixation of mutations at the same nucleotide site or gene, we recovered 100% of a set of known
resistance markers. We also found evidence of positive selection in an additional 39 genomic
regions in resistant isolates. These regions encode pathways of cell wall biosynthesis,
transcriptional regulation and DNA repair. Mutations in these regions could directly confer
resistance or compensate for fitness costs associated with resistance. Functional genetic analysis of
mutations in one gene, ponA1, demonstrated an in vitro growth advantage in the presence of the
drug rifampicin.
The evolution of antibiotic drug resistant bacteria is a major public health concern. To
combat antibiotic resistant infections, we must not only develop new drugs, but also learn to
use existing drugs more effectively. With some exceptions (e.g. in the case of phenotypic
drug tolerance), resistance is encoded in the bacterial genome; therefore, resistance-
associated mutations, whether they are directly causal of resistance or not, can serve as
biomarkers which can be rapidly identified in the clinic by PCR or sequencing-based assays.
These molecular biomarkers allow the determination of a bacterial infection's drug
resistance profile in a matter of hours, instead of the days or weeks required for culture-
based diagnostics. In some cases, this time lag can make the difference between a successful
or unsuccessful treatment.
Here, we describe a method to identify biomarkers of drug resistance in a rapid and unbiased
manner. It consists of sequencing the genomes of bacteria with different resistance
phenotypes, and applying phylogenetic methods and statistical tests for positive selection to
identify variants in the genome that are consistently associated with resistance. The method
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tis amenable to different microbes with different phenotypes of interest. Here, we apply it to
identify biomarkers of drug resistance in Mycobacterium tuberculosis (MTB), the bacterium
responsible for tuberculosis (TB).
The evolution and spread of drug resistant TB threaten to undermine the success of TB
treatment and control programs worldwide. Multi-drug resistant (MDR) TB is defined as TB
that is resistant to isoniazid and rifampicin, the two most effective anti-tubercular drugs.
With a global estimate of 650,000 MDR cases in 20101 and a rising number of cases that are
extensively drug-resistant (XDR; defined as MDR cases that are also resistant to
fluoroquinolones and injectable agents), drug-resistant TB poses a major challenge,
requiring advances in diagnostics, methods of surveillance, and therapeutics.
Resistance in MTB is thought to arise through the serial acquisition of point mutations in
genes encoding drug activating enzymes or targets. Current molecular diagnostics amplify
and detect known drug resistance mutations, and their performance depends on the inclusion
of a comprehensive catalog of these mutations. Although known mutations explain much
resistance in MTB, causative mutations have not been identified in 10-40% of clinically
resistant isolates2 and, even where causative mutations have been identified, there may be
additional variants that contribute to drug resistance.
In addition to classical drug-resistance genes (encoding the protein target of the drug or a
drug-metabolizing enzyme), mutations in three other classes of genes may confer a selective
advantage in the presence of drugs. First, mutations that reduce cell wall permeability or
increase the activity of drug efflux pumps are expected to increase the mean inhibitory
concentrations of drugs, potentially providing an early step toward full-blown drug
resistance3. Second, compensatory mutations that ameliorate the fitness costs of other
resistance mutations can occur and be selected, as seen in both clinical and experimental
evolution studies4. Third, mutator phenotypes can increase the rate at which rare beneficial
mutations occur (though, at the expense of also accumulating deleterious mutations) and
therefore provide a selective advantage in the presence of drug treatment5.
To identify novel genomic regions associated with drug resistance, we performed next-
generation whole genome sequencing of 116 MTB isolates from four categories: (i) eight
epidemiologically-linked clusters of cases (epiclusters) with emergent drug resistance, (ii)
two uniformly drug-sensitive epiclusters, (iii) 35 non epi-linked isolates sampled to
represent the 6 major global lineages of MTB and (iv) 8 isolates from a single patient
displaying emergent resistance (Figure 1). We combined these data with publicly available
genomes of seven isolates. The full 123 MTB sample set include 47 isolates resistant to at
least one TB drug, including nine isolates that are XDR-TB. The resulting dataset captured
substantial genetic diversity, with 24,711 polymorphic sites relative to the H37Rv reference
genome. A genome-wide phylogeny revealed significant population differentiation between
epiclusters, confirmed by high fixation indices (FST > 0.36) between all epicluster pairs
(Figure 1B,C).
We first determined whether drug resistance could be explained by previously known
resistance mutations. To ensure that no resistance mutations were missed, we performed
additional deep targeted sequencing of the known resistance genes in 35 resistant isolates
(15 isolates with no apparent resistance mutations and 20 with at least one known resistance
mutation). We detected mutations in known resistance determinants that had been missed by
the initial whole genome sequencing in two isolates; the remaining 13 had confirmed
resistance to at least one drug that could not be explained by known mutations
(Supplementary Table 1). We did not miss any mutations in the remaining 20 isolates. The
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tisolates with ‘unexplained’ resistance likely harbor novel mutations that encode resistance
and perhaps contribute more generally to the acquisition and maintenance of resistance.
Next, we reasoned that genomic variants (mutations or alleles) under selection in resistant
strains could provide clues about the cellular mechanisms conferring resistance, while also
serving as biomarkers of resistance. We therefore sought to identify genes harboring
mutations that confer a selective advantage to drug resistant strains. Unfortunately, many
commonly used tests to identify genes under positive selection are not well suited to bacteria
such as MTB. Haplotype-based tests for positive selection, often used in humans and other
eukaryotes, cannot be used as genetic diversity in MTB arises primarily by clonal expansion
rather than by mating and homologous recombination among isolates6,7. The widely-used
dN/dS is also not suited to MTB, as the method has low sensitivity in detecting positive
selection in recently diverged sequences from a single species8, and as strong purifying
selection on synonymous mutations in MTB6 can spuriously give rise to high dN/dS scores,
resulting in low specificity. Indeed, dN/dS lacked power and likely specificity when applied
to our MTB dataset, recovering only five of 11 known resistance determinants, while
detecting 143 additional genes (Supplementary Table 2).
Instead, we sought to leverage evolutionary convergence – the repeated and independent
emergence of resistance-associated mutations at specific loci or genes – to develop a test for
selection in clonal bacterial species like MTB7. To identify independently arising mutations,
we reconstructed a phylogenetic tree for the 123 isolates using M. canetti as an outgroup.
Based on this tree, we inferred nonsynonymous and noncoding ancestral sequence changes
and internal resistance states using parsimony. We focused on nonsynonymous mutations as
these were more likely to encode functional protein changes than their synonymous
counterparts. Nevertheless, due to emerging evidence that synonymous sites may also be
under selection for adaptive changes in gene expression or mRNA stability6,9 we also
inferred synonymous mutations (in a secondary analysis reported only in the Supplementary
Note).
We took several precautions to ensure that the reconstructed changes and resistance states in
our analysis were not influenced by possible errors in the tree topology. First, we
reconstructed the phylogeny in triplicate using different methodologies, and removed all
mutations not inferred in all three trees. We also ignored ambiguous mutations from the
ancestral reconstruction, and mutations occurring at branches with lower than 70% bootstrap
support. Second, to remove local uncertainty in the tree topology, we counted ‘close’
changes only once. ‘Close’ changes were any changes that occurred in two isolates
separated by less than the 98th percentile for within-epicluster genetic distance. Third, we
implemented a simplified ‘pairwise’ convergence test in which we compared the most
sensitive to the most resistant isolate in each of 8 epiclusters, ignoring the rest of the
phylogeny entirely (Supplementary Figure 1).
Using the high confidence ancestral reconstruction, we designed a phylogenetic convergence
test (phyC). We first looked for specific mutations with a higher frequency in the resistant
branches compared with the sensitive branches as candidate targets of independent mutation
(TIMs). To distinguish convergence due to positive selection in resistant branches from
patterns expected by chance under neutral evolution10, we assessed the significance of each
candidate TIM relative to the expectation from the observed mutations across the phylogeny.
Briefly, for each TIM with mutations in x resistant branches and y sensitive branches, we
redistributed the x + y hits onto the phylogeny, with branches receiving hits at random, in
proportion to their length. We repeated this permutation 10,000 times to obtain an empirical
P-value assessing the significance of the association of each TIM with resistance. This
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tprocedure controls for the tree topology, including the distribution of resistance phenotypes
across the tree, and for local mutation rate within each TIM.
We then expanded the PhyC test from individual nucleotide sites to encompass whole genes
and intergenic regions as targets. Here, we looked for genes or intergenic regions with a
higher frequency of independently arising mutations anywhere along their length, using the
same framework as described above for the site-specific test.
We applied the PhyC test, for mutations, genes and intergenic regions, to the genomewide
phylogeny of 123 TB isolates. For our analysis, we defined the resistance phenotype as
resistance to any anti-TB drug by conventional drug susceptibility testing so that we would
be able to identify mutations associated with multiple resistances as well as those that confer
resistance to a single drug. We repeated these analyses to identify selection in isolates
resistant to each of the five first-line anti-TB drugs (isoniazid, rifampin, pyrazinamide,
ethambutol, and streptomycin).
As a proof of concept, we assessed the functional impact of the observed mutations within
one of the TIMs identified by the PhyC test. We constructed two ponA1 mutants (carrying 2
of the 3 SNPs (C123G and G1095T) that were most enriched in resistant strains) in an
H37Rv MTB laboratory strain using recombineering and site directed mutagenesis. We then
compared the survival of the two mutant strains to wild type cells and those that lacked the
A1 gene in increasing concentrations of the drugs rifampicin, isoniazid, streptomycinand
ofloxacin.
Results
Targets of independent mutation
PhyC detected all eleven known resistance determinants as significant TIMs. Nine of these
were also identified by a weaker but conservative phylogeny-independent ‘pairwise’
convergence test (Supplementary Tables 3 & 4) developed here. We further identified 39
novel TIMs not previously associated with resistance, consisting of 7 nonsynonymous
coding sites, 2 non coding sites, 28 genes and 2 intergenic regions (p < 0.05) (Figure 2,
Supplementary Table 5). All 9 individual nucleotide site TIMs fell within genes or
intergenic regions also identified as TIMs. We observed that mutations in resistant branches
cluster more closely in the genome than those in sensitive branches and that many of the
TIMs fall in these regions of dense resistant-specific mutations (Supplementary Tables 6 &
7). Mutation 946T in the conserved membrane protein Rv0218 had the highest number of
independent hits in resistant branches of any candidate mutation occurring in eight resistant
branches and on no sensitive branch (P <0.00001). However, because there were more
sensitive than resistant isolates in our dataset, mutations in sensitive branches are far more
prevalent than in resistant branches (compare red and blue histograms of Figure 2). Several
of the TIMs significantly associated with resistance also occur in sensitive branches
(Supplementary Table 5). This suggests that several TIMs may not cause resistance directly,
but rather provide an incremental fitness advantage to resistant strains.
Functions of candidate selected loci
Among the 39 novel genomic regions identified by PhyC, 11 have annotated function (Fig.
4A), 16 belong to a family of genes (PE/PPE) of principally unknown function that is unique
to mycobacteria and constitutes about 10% of the MTB genome (Supplementary Table 5),
and the remaining 12 are of unknown function. We systematically mined the literature on
these genes not previously associated with resistance, noting evidence that many closely
interact with known DR genes (physically or genetically) or drug efflux pumps, alter
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tintrinsic drug resistance in MTB or non-tuberculous mycobacteria, are involved in DNA
repair, replication or recombination or affect cell wall biogenesis.
Previously known resistance loci
Two novel TIMs were located nearby known resistance genes in the genome, suggesting
that they modify or compensate for the phenotypes of the known genes. The first occurs in
the promoter of the known resistance gene rrs, which encodes the 16S RNA component of
the ribosome, a target of aminoglycoside drugs. The second, rpoC (Figure 3), is in the same
operon as rpoB, which codes for the β subunit of RNA polymerase, the main target of the
drug rifampicin. RpoC encodes the interacting β′ subunit, and has been identified as a target
of compensatory mutations modifying the fitness of rifampicin-resistant isolates of both
MTB and S. typhimurium11-14. Prior studies have shown that substitutions in rpoC are
frequent in clinical rifampicin resistant isolates with known rpoB mutations and that the
relative fitness of rpoC/rpoB mutants in vitro is higher than those with rpoB mutations
alone12-13. Some rpoC mutations in S. typhimurium also confer low-level rifampicin
resistance, suggesting that rifampin-resistance phenotypes may be the result of additive
substitutions in different genes13. Among the 43 rifampicin resistant isolates in our
collection, 13 (30%) harbored rpoC substitutions that did not appear in any rifampicin
sensitive isolates.
Unexplained drug resistance
We determined whether nonsynonymous mutations in the TIMs could explain resistance in
the 13 isolates without known drug resistance mutations. For each drug and isolate we
identified all mutations in the candidate genes excluding mutations occurring in any isolate
sensitive to that drug. Although no single candidate mutation or gene was found to account
for all the unexplained drug-specific resistance, two of six isolates with unexplained
kanamycin resistance harbored mutations in PPE60 (Supplementary Table 8). Eight of the
13 (62%) isolates exhibited changes in at least one TIM, with four of the isolates exhibiting
changes in two or more.
Drug-efflux pumps
Although no efflux pumps were identified among genes that met our statistical criteria for
TIMs, we found that several efflux pumps, including the ABC transporters Rv0194 and
Rv1463, have a larger number of independent mutations in resistant strains relative to
sensitive strain.
DNA repair
Another of the novel TIMs, dnaQ, encodes a component of DNA polymerase III that
provides “proof-reading” activity during DNA replication. Several dnaQ mutations in E. coli
yield strong mutator phenotypes15. To date, no similar phenotype has been described in
MTB, although dnaQ variants are not uncommon among clinical isolates16.
The PE/PPE gene family as a target of independent mutation
Sixteen novel TIMs are members of the PE/PPE family, the majority of which are within the
PGRS sub-family; this was the only gene group significantly enriched in the convergence
analysis. Multiple members of this family are surface-exposed cell wall proteins; some
affect cell wall structure and permeability and some have been shown to be antigens17. PE/
PPE genes contain an extremely high density of substitutions, and were therefore excluded
from the genomewide phylogeny. As a result, it is expected (although not guaranteed) that
these genes would be enriched for conflicting phylogenetic signal (homoplasy), but not
necessarily that homoplasic mutations be associated with resistance. The association of PE/
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tPPE genes with drug resistance is therefore noteworthy. Due to the high genetic diversity in
these genes, the association may reflect random fixation of this diversity during population
bottlenecks that occur during antibiotic treatment, rather than genuine positive selection on
resistant isolates. In other words, resistant isolates may be descended from the survivors of
severe bottlenecks, during which neutral mutations repeatedly become fixed, and these
mutations are most readily observed in diverse loci like PE/PPE genes. However, we cannot
rule out a possible functional role of PE/PPE genes in the evolution of resistance – for
example, PPE60 is one of the best candidates to account for some of the unexplained
kanamycin resistant isolates (see below, and Supplementary Table 8).
Cell wall homeostasis
Five novel TIMs contribute to MTB cell wall biogenesis or remodeling. The structure of the
mycobacterial cell wall is unique among prokaryotes in that in addition to the peptidoglycan
layer typical of most bacteria, it contains several outer layers characterized by unusual
complex lipids (Table 1 and Supplementary Figure 2). These layers contribute to the
permeability barrier that underlies the intrinsic antibiotic resistance of most mycobacteria18.
Multiple TB drugs target structures in the cell wall, and many of the known resistance genes
code for enzymes in cell wall lipid pathways. Three of the five genes (ppsA, pks12 and pks3)
participate in the biosynthesis and translocation of the surface exposed lipids including
phthiocerol dimycocerosate (PDIM) 19-21 while the remaining two (murD and ponA1)
contribute to the biosynthesis and homeostasis of the cell wall component, peptidoglycan22.
Deletion of ppsA, depletion of pks12 and depletion of ponA1 each affect susceptibility to
antibiotics in non-tuberculous mycobacteria and/or MTB23-25. Deletion of pks12 has been
recently shown to increase drug resistance in M. avium through a cell wall remodeling
pathway26. In addition, pks12 had a synonymous site that was a significant TIM
(Supplementary Table 9)
Functional Analysis of PonA1 Mutants
In the presence of the drug rifampicin, the strain carrying the ponA1 G1095T mutation had a
4-6 fold survival advantage at a concentration of 0.00125μg/ml of drug (Figure 4). The MIC
to rifampicin for this mutant is estimated at 0.0025 μg/ml or 2-fold higher than wildtype
MIC (0.00125 μg/ml). In contrast, the ponA1 C123G mutant strain showed no growth
advantage in the presence of rifampicin, and neither mutant demonstrated a growth
advantage when grown in the presence of isoniazid, streptomycin or ofloxacin. The 1095
site maps close to the ponA1 transpeptidase domain catalytic site, raising the possibility that
the SNP inactivates this enzymatic activity; this is supported by the finding that the ponA1
deletion mutant demonstrates a similar rifampicin resistance phenotype (Figure 4).
Discussion
This work describes a comprehensive genomewide search for genes under selection in
clinically resistant MTB isolates. Convergent evolution provides the basis for a highly
sensitive test for selection that recovered all of a set of 11 known drug resistance
determinants, and is easily generalizable to the study of other types of bacteria. Our method
involves sequencing the genomes of related bacteria with different phenotypes of interest (in
this case, antibiotic resistance), reconstructing a phylogeny, and identifying targets of
convergent evolution using a simple statistical test. While the method relies on a
genomewide phylogeny, it can accommodate recombination, provided that it is not so
rampant as to completely obscure the phylogeny. Recombinant regions often conflict with
the genomewide phylogeny, allowing them to be identified by our method as targets of
convergent evolution if they are consistently associated with the phenotype of interest, but
not if they are randomly distributed among genomes with different phenotypes. The method
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tis therefore amenable to bacteria with a range of recombination rates. It provides a rapid and
unbiased means of identifying molecular biomarkers that are predictive of phenotypes of
interest.
Applying this method to MTB, we identified 39 genes and intergenic regions newly
associated with resistance. While several of these selected mutations occur in genes that are
either nearby known DR loci in the genome or are mutator genes in other organisms, a
preponderance were associated with cell wall permeability phenotypes. This suggests that
stable drug resistance phenotypes may evolve through a complex step-wise process
involving cell wall remodeling. Our finding that a ponA1 mutation (G1095T) identified as a
TIM conferred a fitness advantage in the presence of rifampicin is consistent with this
model.
The relevance of cell wall remodeling pathways to drug resistance is also highlighted by two
recent studies that compared resistant isolates to their drug sensitive precursors. In one, the
investigators noted increased levels of PDIM and peptidoglycan precursors and up-
regulation of the PDIM biosynthetic operon (including ppsA) in rifampicin resistant strains.
Interestingly we identified ppsA as a TIM in strains resistant to rifampicin (95% of which
had nonsynonymous mutations in rpoB, Supplementary Table 10) in addition to other drugs,
raising the possibility that rifampin resistance-causing rpoB mutations may lead to
alterations in cell wall metabolism possibly a result of altered transcription27. The second
study documented the occurrence of eleven new non-synonymous mutations in serial MTB
isolates from three patients who developed increasing levels of resistance during anti-TB
therapy. Seven of the mutations occurred in genes involved in cell wall biosynthesis or
transport including fadD32 and Rv1739c, an ABC transporter. Although none of these
overlapped with the TIMS identified in this study, the enrichment of mutations in genes
associated with cell wall biosynthetic pathways among progressively drug resistant strains is
consistent with our findings and further supports the hypothesis that these changes reflect
accommodation to drug exposure28.
The genomic TIMs we have identified here are associated with drug resistance and may
represent changes that confer a selective advantage in the presence of drug. In aggregate,
they provide promising new targets for molecular diagnostics and development of
therapeutics against drug resistance in MTB.
Online Methods
Institutional review board
The study was evaluated by Institutional Review Boards at the Harvard School of Public
Health, the Broad Institute of MIT and Harvard, and the Centers for Disease Control and
Prevention where it was determined that it met criteria for exemption from human subject
review.
Isolate selection
We assembled an archive of sensitive and resistant isolates that capture a range of
Mycobacterium tuberculosis (MTB) lineages, geographic sources and resistance profiles.
Building on our previous molecular epidemiological studies (Supplementary Table 11 and
references within) we aimed to include sets of progressively resistant isolates, sampled
either from community transmission chains or from individuals with chronic disease. These
sets included isolates from 11 such micro-epidemics (‘epiclustered’ isolates), as defined by
molecular fingerprinting, chosen to include the most sensitive and most resistant members of
the cluster as well as 8 progressively resistant isolates from a single patient over time. To
obtain a measure of background evolution restricted to sensitive isolates and avoid mis-
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tidentifying highly variable loci as associated with drug resistance, we included 23
geographically diverse drug sensitive isolates and additional isolates from two drug sensitive
epiclusters.
To increase the diversity of the sample, we included 11 additional resistant isolates even
when a less resistant progenitor was not available. We also included 3 isolates that had been
spontaneously evolved in vitro and manifested an aminoglycoside resistance phenotype that
was unexplained by targeted sequencing of all previously known resistance genes. In all,
116 MTB isolates were selected for sequencing described in detail in Supplementary Table
11A.
We added 7 publicly available MTB genomes to our alignment, including two drug sensitive
Beijing lineage isolates, the latter of which were missing from our sampled isolates thus far.
Isolates obtained from public sources are detailed in Supplementary Table 11B. There is no
established method to determine the power of genomic analyses performed with this sample
size, but the strain set studied here is among the largest set of drug resistant MTB strains
sequenced to date.
Of the 123 total isolates, 47 were resistant to one or more drugs (Supplementary Table 11).
Eighty three isolates belonged to 14 distinct epiclusters, and the rest were isolates with a
unique molecular fingerprint. Twelve clusters had one or more resistant isolates. One other
publicly available genome from the species Mycobacterium canetti was included to serve as
a phylogenetic outgroup.
Resistance phenotype
We defined a “broad resistance” phenotype as resistance to any anti-TB drug by
conventional drug susceptibility testing. We used this “broad resistance” as our primary
phenotype of interest as our goal was to identify genes and mutations associated with
resistance to at least one drug, but potentially many. As a secondary, more specific
phenotype of interest, we used resistance to each of the 5 first line anti-TB drugs (isoniazid,
rifampin, pyrazinamide, ethambutol, and streptomycin). Resistance status to first line anti-
TB drugs had much fewer missing data points than resistance to the other drugs
(Supplementary Table 11).
Sequencing, Alignment, and SNP calling
DNA was extracted from all isolates using standard methods and sequenced on an Illumina
GAIIx instrument using reads of 36bp length or more. Sequence reads were aligned to the
reference genome sequence for H37Rv using MAQ40. Reads that aligned with more than 3
mismatches in the first 24bp or that aligned to multiple locations were discarded. SNPs were
called with a minimum depth of 20X, and consensus quality score of 20. The required
maximum mapping quality of reads covering the SNP was set at 50. SNPs within 5bp of an
indel (insertion or deletion) or did not have an adjacent consensus quality of 20 were also
discarded. Refer to the supplementary note for further details.
FST and dN/dS analyses
Fixation index (FST) and dN/dS rates were computed using standard methods detailed in the
supplementary note.
Phylogeny construction
The phylogeny was constructed based on the whole MTB genome multiple alignment, as
MTB populations are thought to be predominantly clonal, with most of the genome
supporting a single consensus phylogeny not impacted significantly by recombination6. A
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tsuperset of SNPs relative to reference strain H37Rv35 was created across all clinical isolates
from the MAQ SNP reports. SNPs occurring in repetitive elements including transposases,
PE/PPE/PGRS genes, and phiRV1 members (273 genes, 10% of genome) (genes listed in
reference41) were excluded to avoid any concern about inaccuracies in the read alignment in
those portions of the genome. Furthermore, SNPs in an additional 39 genes previously
associated with drug resistance38 were also removed to exclude the possibility that
homoplasy of drug resistance mutations would significantly alter the phylogeny. After
applying these filters to the initial set of 24,711 SNPs, the 23,393 remaining SNPs were
concatenated and used to construct phylogenetic trees using three methods. Using the
PHYLIP dnapars algorithm v3.6842 we constructed a parsimony phylogenetic tree using
default parameters with M. canettii as an outgroup root. We constructed a second phylogeny
with Bayesian Markov chain Monte Carlo (MCMC) methods as implemented in the package
MrBayes v3.242 using the GTR model and a stop criterion of standard deviation of split
frequencies of <0.05. We constructed a maximum likelihood tree using PhyML v3.044 using
the GTR model with 8 categories for the gamma model with and without M. canetti to
determine the location of the root. One hundred bootstrap resamplings were performed for
each tree, except for the Bayesian tree where posterior probabilities on the branches was
used as a measure of confidence. A phylogeny was also constructed using the full SNP set
(without excluding SNPs in repetitive elements or known drug resistance genes), and only
minor differences in the terminal branches of the tree were found. We used the trees
constructed with exclusion of SNPs in repetitive elements and known drug resistant genes
for all subsequent analyses.
Phylogenetic convergence test for selection (PhyC)
The phylogenetic convergence test used sequences from all branches of the phylogeny.
Ancestral nucleotide non-synonymous (or intergenic) substitutions were reconstructed along
each branch using both parsimony and maximum likelihood criteria using the R v2.14.1
package ape v3.0.145. Each branch was assigned a resistant or sensitive label using
parsimony. The reconstruction was performed in triplicate for the three phylogenies
(Bayesian, parsimony and maximum likelihood). We excluded all ambiguously
reconstructed states (<90% probability for maximum likelihood reconstruction). We
considered changes occurring along the terminal and deep branches of the phylogenetic tree,
but excluded changes occurring at branches with bootstrap support or posterior probability
of <70%. For each nucleotide site in the genome, we counted the number of convergent
SNPs (to the same base) in resistant and sensitive branches. Given that some background
convergence is expected due to neutral mutation and sequence error even without positive
selection10, we assessed the significance of each convergent SNP compared to the empirical
background distribution (Supplementary Figure 3). For a SNP that converges in x resistant
and y sensitive branches, we sampled x+y branches from the distribution of all SNPs in all
branches genomewide, repeated this 10,000 times, and recorded the proportion of times
substitutions were observed ≥x resistant and ≤y sensitive branches. This proportion serves as
an empirical p-value for an unexpectedly high level of convergence among resistant
branches, suggesting the action of selection. To be considered a candidate for positive
selection, we required a SNP to have p < 0.05 across all phylogenetic and ancestral
reconstruction methods.
As multiple different SNPs within the same gene might nevertheless code for similar
resistance phenotypes, we expanded the convergence test beyond individual SNPs to include
whole genes and intergenic regions. In this method, branches were defined as convergent if
they contained a SNP in the same gene or region, even if the SNPs occurred at different
nucleotide sites. For each gene and intergenic region in the genome we counted the number
of SNPs occurring within the region boundaries, counting at most one SNP for each branch
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resampling strategy as for SNP-based convergence, we generated a list of significant region-
based convergence among resistant branches. Supplementary Table 5 details the genes
found to be under selection using the phylogeny based convergence method. See the
supplementary note for details on the pairwise convergence test and the analysis of the
density of resistance-specific mutations.
Selection testing by first line drug phenotype
PhyC, and other supplementary tests for selection were performed similarly for resistance to
each of the five first line TB drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, and
streptomycin (Supplementary Tables 10,12-15). The genes significant by the “broad
resistance” phenotype and resistance to isoniazid, rifampicin, and streptomycin are highly
similar with few exceptions. This is likely a result of how closely associated resistance to
isoniazid, rifampicin, ethambutol, and streptomycin are (Supplementary Table 11, for
example 82% of isolates resistant to either isoniazid or rifampin were resistant to both). The
number of significant genes for pyrazinamide was significantly lower than the other drugs
likely resulting from the larger number of isolates with a missing resistance phenotype to
this drug, and a resultant low statistical power.
SNPs detected in genes under selection
Supplementary Table 16 lists all the SNPs seen in the TIMs in resistant isolates. SNPs were
called relative to the preceding (ancestral) node for each isolate in the phylogenetic tree.
Supplementary Table 17 provides a multiple alignment of the genetic sequence for all SNP
sites in the TIMs (these include sites occurring in resistant strains only, sensitive strains only
and SNP sites occurring in both types of strains).
Candidate genes variants in isolates with unexplained resistance
We identified nonsynonymous SNPs in the genes under positive selection in isolates with
unexplained resistance. We filtered out SNPs in these genes that occurred in any isolates
sensitive to each drug. The results are detailed in Supplementary Table 8.
M. tuberculosis mutant generation
Rv0050, encoding ponA1, was replaced with a hygromycin resistance cassette using
mycobacterial recombineering in the H37Rv host strain. The ponA1∷hyg replacement was
confirmed by PCR and whole genome sequencing. As we sought to identify mutants more
likely to be independently causative of resistance we focused on ponA1 SNP alleles C123G
and G1095T as these occurred in mostly drug resistant clinical strains, and the third site
(1891) alleles (C/T) were more prevalent in susceptible strains. SNP alleles in ponA1 were
generated by site directed mutagenesis and Sanger sequence confirmed. Wildtype or SNP
alleles in ponA1 were cloned under the control of a constitutive promoter and integrated in
the M. tuberculosis genome as single copies at the L5 phage integration site.
MIC assays
All strains were grown in Middlebrook 7H9 medium supplemented with 0.25% glycerol,
10% oleic acid-albumin-dextrose-catalase, and 0.05% Tween-80. For MIC calculations, the
strains ΔponA1, ΔponA1 L5∷ponA1wildtype, ΔponA1 L5∷ponA1C123G, and Δ ponA1 L5∷
ponA1G1095T were grown until mid-log phase (0.5 – 0.8 spectroscopic optic density at
600nm (OD600)) and then diluted to a calculated starting OD600 of 0.006 and grown ± drug
for 6 days at 37°C with shaking. All conditions were done in duplicate. Two sets of
duplicate experiments were performed at slightly different drug concentrations. Percent
survival is calculated by normalizing the OD600 measurements of each strain to its
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trespective untreated control. The MIC was defined as the drug concentration that inhibits
growth to 1% or less of the untreated control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Characteristics of sequenced TB isolates: (A) Geographic distribution of sampled isolates
(circle size is proportional to the number of isolates sampled; circle color refers to TB
lineage. (B) Parsimony phylogenetic tree with node bootstrap support. Root length not to
scale. Epiclusters are merged into triangles for clarity, with the exception of two
paraphyletic epiclusters: Peru2 and Russia1. (C) Genetic differentiation between the 14
epiclusters (higher FST reflects higher differentiation). FST values provided in
Supplementary Table 19.
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Candidate genes under selection in resistant MTB. Circular plot of gene locations. Outer
black lines represent: the 11 benchmark drug resistance genes in the H37Rv reference
genome (red text). Inner red lines represent locations of targets of independent mutation
(TIMs). Four novel TIMs of interest are named in black text. The innermost barplot shows
the number of mutations per gene or intergenic region, in resistant (red) or sensitive (blue)
isolates. Plotted using circos29.
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Evolutionary convergence at the gene level in rpoC. Resistant branches (inferred by
parsimony, and usually involving progressive resistance to several drugs) and strain names
are colored red; sensitive branches in black. Stars on the phylogeny designate inferred
sequence changes in rpoC: Blue stars denote changes in resistant branches (10 in total),
black in sensitive branches (6 in total). Nucleotides in the multiple sequence alignment are
also colored blue or black accordingly. Sites shown in the multiple alignment are (left to
right) 763884, 764181, 764580, 764819, 765150, 765171, 765230, 765462, 765463,
765482, 765619, 766467, 766488, 766645, 767060 (H37Rv coordinates).
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MTB ponA1 mutant survival in the presence of the drug rifampicin. (A) Bacterial survival
(percent of untreated control OD600 absorbance) under increasing concentrations of
rifampicin for ΔponA1 (ponA1 deletion mutant), Δ∷wildtype (ponA1 deletion mutant
complemented with the wildtype ponA1 gene), Δ∷G1095T (mutant complemented with
ponA1 carrying the G1095T allele), and Δ∷C123G (mutant complemented with ponA1
carrying the C123G allele) (B) Bacterial survival (as in A) of strains cultured in the presence
of 0.00125μg/ml of rifampicin. The two-sided t-test comparing survival between wildtype
and Δ∷G1095T was significant with a P-value of 0.006. Error bars represent the standard
deviation. Four replicate experiments were performed.
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